Open access
Oct 2026
Skin Toxic Effects and Survival With Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Carcinoma
It is suggested that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.
Zachariah Thomas, Cindy Y. Jiang, Patrick Speck et al.
· JAMA Network Open · 0 citations